1. Mourad S, Brown J, Farquhar C (2017) Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev 1(1):CD12103
2. Bodri D, Guillén JJ, Trullenque M, Schwenn K, Esteve C, Coll O (2010) Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril 93(7):2418–2420
3. (2024) Bericht der Kommission zur reproduktiven Selbstbestimmung und Fortpflanzungsmedizin. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/K/Kom-rSF/Abschlussbericht_Kom-rSF.pdf
4. Söderström-Anttila V, Miettinen A, Rotkirch A, Nuojua-Huttunen S, Poranen A‑K, Sälevaara M et al (2016) Short- and long-term health consequences and current satisfaction levels for altruistic anonymous, identity-release and known oocyte donors. Hum Reprod 31(3):597–606
5. Rizzuto I, Behrens RF, Smith LA (2019) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 6(6):CD8215